Delray Beach, FL, July 20, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global high-throughput screening (HTS) market will grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a CAGR of 10.7% during the forecast period. Market growth is driven by increasing pharmaceutical and biotechnology R&D investments, growing adoption of automated drug discovery platforms, rising government funding and venture capital investments, and technological advancements in high-content screening, cell-based assays, artificial intelligence-enabled analytics, and laboratory automation. The expanding use of outsourced drug discovery models, 3D cell cultures, organoids, and advanced screening platforms is further accelerating market growth.
Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950
Key players: Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity, Inc. (US), Tecan Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Corning Incorporated (US), Sartorius AG (Germany), Charles River Laboratories (US), Eurofins Scientific SE (Luxembourg), and Hamilton Company (US).
High-throughput screening has become a cornerstone of modern drug discovery by enabling researchers to rapidly evaluate thousands to millions of compounds, genes, and biological targets. As pharmaceutical and biotechnology companies accelerate drug development pipelines, HTS technologies are helping reduce discovery timelines, improve hit identification, and enhance target validation. Advances in automation, high-content imaging, AI-powered data analysis, phenotypic screening, and biologically relevant models such as 3D cell cultures and organoids are significantly improving screening efficiency and decision-making across research workflows.
The HTS market continues to evolve through increasing automation, integration of artificial intelligence, and adoption of biologically relevant screening models. Pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic research institutes are investing in automated liquid handling systems, microplate technologies, imaging platforms, assay kits, and laboratory informatics to improve screening throughput and reproducibility. Growing outsourcing of early-stage drug discovery and expanding collaborations between pharmaceutical companies, CROs, and research institutions are further strengthening market expansion.
The HTS industry is shifting toward intelligent, highly automated drug discovery ecosystems that integrate robotics, high-content imaging, AI-enabled analytics, and cloud-based laboratory informatics. Organizations capable of combining advanced screening technologies with scalable automation, sophisticated data analysis, and biologically relevant assay platforms will be well positioned to address the growing complexity of modern drug discovery. Continued investment in precision medicine, biologics, and next-generation therapeutic development is expected to create substantial long-term opportunities for HTS technology providers.
